High cholesterol is a common finding in routine UK health checks, and the question that most often follows is: "Do I need to be on a statin?" The honest answer is that it depends less on any single cholesterol number and more on your overall cardiovascular risk. UK practice is guided by NICE guideline CG181 (updated as NG238), which sets a clear framework for who is offered a statin, when, and at what dose. This article walks through cholesterol itself, how UK clinicians assess risk with QRISK3, when statins are offered, how they are monitored, and what happens if the first statin is not the right fit.
What cholesterol is and why it matters
Cholesterol is a fatty substance carried in the blood by particles called lipoproteins. When a blood test measures your cholesterol, it usually reports several components:
- Total cholesterol — the overall figure.
- LDL (low-density lipoprotein) cholesterol — often called "bad" cholesterol because higher levels are linked with more plaque in artery walls.
- HDL (high-density lipoprotein) cholesterol — often called "good" cholesterol because it carries cholesterol away from artery walls.
- Non-HDL cholesterol — total cholesterol minus HDL. UK practice increasingly uses non-HDL rather than LDL alone because it captures all the atherogenic (artery-damaging) particles.
- Triglycerides — another type of blood fat, influenced by diet, alcohol, weight and some medications.
The reason cholesterol matters is straightforward: over years, higher LDL and non-HDL cholesterol drives atherosclerosis — the fatty build-up in arteries that underlies heart attacks and most strokes. Lowering LDL lowers cardiovascular event risk, and that relationship is one of the most consistent findings in modern cardiology.
Lifestyle measures — always first-line, always parallel
Whether or not medication is on the table, lifestyle sits at the base of every UK lipid-management pathway. That means a Mediterranean-style diet emphasising vegetables, wholegrains, pulses, oily fish and unsaturated fats, with less saturated fat, ultra-processed food and refined sugar. Regular physical activity — the NHS aim is at least 150 minutes of moderate activity weekly — plus not smoking, moderate alcohol and a healthy weight all lower cardiovascular risk independently of cholesterol.
Even for patients who go on to statins, these measures remain part of the plan. Statins are additive; they are not a licence to stop taking care of the rest.
How cardiovascular risk is estimated in the UK — QRISK3
Rather than treating cholesterol in isolation, UK practice uses QRISK3, an NHS-endorsed risk calculator that estimates the probability of a heart attack or stroke over the next 10 years. It combines age, sex, ethnicity, blood pressure, cholesterol ratio, BMI, smoking status, family history of premature heart disease, diabetes, chronic kidney disease, atrial fibrillation, migraine, rheumatoid arthritis, mental illness, corticosteroid use and other factors.
The output is a percentage — for example, "12% 10-year risk". That number lets the clinician and patient have a concrete conversation about whether medication is likely to be worth it, given the individual's picture rather than a generic threshold.
When statins are considered — primary vs secondary prevention
UK guidance splits the population into two groups: those who have never had a cardiovascular event (primary prevention) and those who already have (secondary prevention).
Primary prevention
For primary prevention, NICE recommends offering a statin to adults whose estimated 10-year cardiovascular risk on QRISK3 is 10% or higher, after a shared decision about benefits, risks, side effects and alternatives. The choice to take a statin below the 10% threshold can still be reasonable if a person's individual risk profile suggests they will benefit — for example, strong family history not fully captured by the tool. Adults with type 1 diabetes, chronic kidney disease of certain stages, or familial hypercholesterolaemia have their own recommendations that sit alongside QRISK3.
Secondary prevention
For anyone with established cardiovascular disease — previous heart attack, stroke, transient ischaemic attack, angina, peripheral arterial disease or coronary revascularisation — a statin is offered as standard, without needing to calculate QRISK3. The starting dose is higher because the ongoing risk of a further event is higher.
The statin ladder and dosing
Not all statins are used at the same intensity. UK practice classifies statins by how much they typically lower LDL cholesterol at a given dose. Atorvastatin is the usual first-line in both primary and secondary prevention:
- Primary prevention: atorvastatin 20 mg once daily is the usual starting dose.
- Secondary prevention: atorvastatin 80 mg once daily is the usual target, with 40 mg an option where 80 mg is not tolerated or is contraindicated.
Where atorvastatin is not suitable or not tolerated, rosuvastatin is another high-intensity option, often used at 10–40 mg. Simvastatin (typically 20–40 mg) is a moderate-intensity statin and remains in use, particularly for patients who are stable on it long-term, though it has more interactions and is generally not the first choice for new starts at high intensity. Pravastatin and fluvastatin are less commonly used first-line but can be options in specific circumstances.
What "intensity" means in practice
| Intensity | Approximate LDL reduction | Typical UK examples |
|---|---|---|
| High | ≥40% | Atorvastatin 20–80 mg; rosuvastatin 10–40 mg |
| Moderate | 30–39% | Atorvastatin 10 mg; simvastatin 20–40 mg; rosuvastatin 5 mg |
| Low | <30% | Simvastatin 10 mg; pravastatin 10–20 mg; fluvastatin 20–40 mg |
These are indicative figures; the response for any individual varies, which is why bloods are checked after starting.
Monitoring — what happens after you start
Before starting a statin, baseline blood tests are usually done: a full lipid profile, liver function tests (LFTs), thyroid function, HbA1c, and renal function. Creatine kinase (CK) is checked in people at higher risk of muscle problems or with existing muscle symptoms.
After starting, UK practice checks non-HDL cholesterol at around three months. The aim in primary prevention is a reduction of non-HDL cholesterol of 40% or more from baseline. If that is not achieved, the clinician will look at adherence, lifestyle and whether the dose needs to be increased or the statin switched. LFTs are typically repeated within 12 months, and full lipid profile again within a year. Ongoing review is annual for stable patients.
Side effects — and what actually happens in practice
The most commonly reported side effect of statins is muscle aches. Large randomised trials suggest that true statin-related muscle problems are less common than the number of reports would imply — many patients who report muscle symptoms while on a statin also report the same symptoms on placebo. That does not mean anyone's experience is invalid; it means the practical answer is a structured trial, not immediate abandonment.
Where muscle symptoms are troublesome, the usual approach is to pause the statin, allow symptoms to settle, and then rechallenge — often with a lower dose of the same statin, an alternate-day regimen, or a switch to a different statin. Severe muscle pain with dark urine (suggesting rhabdomyolysis) is rare but needs urgent review. Other recognised effects include a small increase in liver enzymes (usually not clinically significant), a slightly higher risk of new-onset type 2 diabetes in predisposed individuals, and — rarely — headache or gastrointestinal upset.
When to switch or add in — ezetimibe, PCSK9 inhibitors and bempedoic acid
If a person is on the highest tolerated statin dose but non-HDL or LDL cholesterol remains above target, UK guidance supports adding ezetimibe, a well-tolerated oral tablet that reduces cholesterol absorption. Ezetimibe can also be used in people who genuinely cannot tolerate any statin.
For patients at very high cardiovascular risk who remain above target despite maximum tolerated statin plus ezetimibe — particularly those with familial hypercholesterolaemia or established atherosclerotic disease — specialist services can consider PCSK9 inhibitors (evolocumab, alirocumab) or bempedoic acid. These are prescribed via NHS lipid clinics under NICE technology appraisals, and their use is more targeted than routine primary prevention.
What a consultation with Farmeci covers
A Farmeci consultation for high cholesterol typically starts with a structured review of your recent lipid profile, other cardiovascular risk factors, current medication and lifestyle. Where a QRISK3 calculation and baseline bloods have not been done recently, the clinician will signpost the appropriate NHS route — usually your GP for the full assessment. Where a statin is a reasonable option and safe in your specific case, that can be discussed within the consultation. This sits alongside — not in place of — your NHS care. For related background on how metabolic conditions interact with cardiovascular risk, our overview of GLP-1 receptor agonists and the General Wellbeing hub may be useful.
The bigger picture
A statin decision is rarely just about a cholesterol number. It is a conversation about the size of your cardiovascular risk, the potential benefit, the potential downsides, what else you can change, and what you would like to do. UK guidance provides the framework; QRISK3 provides the numbers; a clinician provides the context. Together, that is how the decision is made.